GlobeNewswire by notified

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS

Share
Bid procedure, 2021-10-01
BondsSWEDISH GOVERNMENT: 1062. SE0013935319. 2031-05-12

SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24


Bid date2021-10-01
Bid times09.00-10.00 (CET/CEST) on the Bid date
Requested volume (corresponding nominal amount)1062: 500 mln SEK +/-250 mln SEK

1063: 500 mln SEK +/-250 mln SEK


Highest permitted bid volume (corresponding nominal amount)1062: 500 mln SEK per bid

1063: 500 mln SEK per bid


Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bid
Expected allocation timeNot later than 10.15 (CET/CEST) on the Bid date
Delivery and payment date2021-10-05
Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383

Stockholm, 2021-09-24

This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Biotalys Awarded Multi-Year Grant to Develop New Biological Solutions for Cowpea and Other Legumes20.10.2021 07:00:00 CEST | Press release

Ghent, BELGIUM, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Press release –inside information Biotalys Awarded Multi-Year Grant to Develop New Biological Solutions for Cowpea and Other Legumes Company to receive $5.98million in total from the Bill & Melinda Gates Foundation to leverage its AGROBODY™ technology platform Ghent, BELGIUM,and Research Triangle Park (NC), UNITED STATES– 20October2021, 07:00 CEST –Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions, today announced it has been awarded a multi-year grant from the Bill & Melinda Gates Foundation to discover novel antifungal biocontrols for deployment to smallholder farmers. The project, identified as “Agrobodies for Crop Protection”, focuses on leveraging Biotalys’ AGROBODY Foundry™ technology platform to discover novel protein-based biofungicides with the ability to control Cercosporacanescens, the causative agent of leaf spot di

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in the first nine months – outlook for 2021 raised20.10.2021 07:00:00 CEST | Press release

Basel, 20 October 2021 Group sales up 8%1 at constant exchange rates (CER); 6% in Swiss francsPharmaceuticals Division sales grow 5% in the third quarter and are now in line with the prior year for the first nine months; continued strong growth of newly launched medicinesDiagnostics Division sales grow 18% in the third quarter and 39% in the first nine months due to high demand for COVID-19 tests, a strong recovery in the base business and the newly launched diagnostics platformsHighlights in the third quarter:FDA approves cancer immunotherapy Tecentriq (early-stage lung cancer) and grants Priority Review for eye medicine faricimabPositive study results for Polivy (blood cancer) and Ronapreve (COVID-19)FDA grants Breakthrough Therapy Designation to gantenerumab (Alzheimer’s disease);final study results expected in second half of 2022Share purchase agreement with long-term partner TIB Molbiol to expand molecular diagnostics portfolioOutlook raised SalesCHF millionsAs % of sales% changeJ

Active Biotech och NeoTX meddelar idag att den första patienten har rekryterats i den kliniska fas IIa-studien med naptumomab estafenatox i kombination med docetaxel i patienter med lungcancer20.10.2021 07:00:00 CEST | Pressemelding

Lund, 20 Oktober 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och dess samarbetspartner NeoTX meddelar idag att den första patienten har rekryterats i den kliniska fas IIa-studien med naptumomab estafenatox (naptumomab) i kombination med docetaxel i patienter med avancerad icke-småcellig lungcancer (NSCLC). Den öppna fas IIa-studien kommer att utvärdera naptumomab i kombination med docetaxel i patienter som tidigare behandlats med checkpoint-hämmare och har avancerad eller metastaserande NSCLC och kommer att bedrivas i USA. Det primära studiemålet är objektiv responsfrekvens mätt enligt RECIST 1.1-kriterier. Studien kommer också att utvärdera säkerhet, responsduration, progressionsfri överlevnad, total överlevnad, farmakokinetik och farmakodynamik. För mer information om studien, besök clinicaltrials.gov. (NCT04880863). "Vi är mycket nöjda med att NeoTX tar nästa steg i utvecklingen av naptumomab i NSCLC, en sjukdom med ett stort medicinskt behov, och ser fram emot att följa utveckli

TGS, BGP, CGG Sign Agreement with Staatsolie for Multi-Client Programs Offshore Suriname20.10.2021 07:00:00 CEST | Press release

OSLO, Norway (19 October 2021) - TGS, a global provider of energy data and intelligence, in a consortium with CGG and BGP, today announced the signature of a multi-client agreement with Staatsolie, the state-owned company leading the development of the energy industry in the Republic of Suriname. The agreement allows the consortium to acquire, promote and license multi-client seismic programs, including new 3D acquisition and legacy data reprocessing, in the shallow water acreage offshore Suriname. Suriname’s shallow offshore acreage includes three blocks recently awarded, and current open acreage is slated to be offered in a competitive bid round for 2023. The new seismic data from the consortium’s multi-client programs will be instrumental in accurately delineating the prospectivity and potential of this underexplored area and is on trend with the recent material discoveries announced on the prolific block 58. Plans are in place to start acquiring the new 3D seismic data in the shall

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo20.10.2021 07:00:00 CEST | Press release

-Finalresults from pilot study of linzagolix for the treatment of severe adenomyosisto be presented in a second poster - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland October 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of clinical data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for the treatment of uterine fibroids as well as final data from a pilot study of linzagolix for the treatment of severe adenomyosis at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo, being held October 17-20, 2021. “Enlarged uterine volume is an important driver of abnormal bleeding and pain associated with uterine fibroids; moreover, bulk and pressure symptoms may strongly impact women’s quality of life,” said Jacques Donnez, M.D., Ph.D., a key opinion leader in gynecolog

Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)20.10.2021 07:00:00 CEST | Press release

Lund, October 20, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox (naptumomab), in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The phase IIa, open label trial in US will assess naptumomab in combination with docetaxel in patients who had been previously treated with checkpoint inhibitors and have advanced or metastatic NSCLC. The primary endpoint is objective response rate as measured by RECIST 1.1 criteria. The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics, and pharmacodynamics. For more information about the trial, visit https://clinicaltrials.gov. NCT04880863. “We are very pleased that NeoTX takes the next step in the development of Naptumomab in NSCLC, a disease with a high unmet medical need, and are excited to follow the progress of

REC Silicon - Third quarter 2021 results20.10.2021 06:55:00 CEST | Press release

Oslo, Norway – October 20, 2021: REC Silicon ASA (REC Silicon) reported third quarter 2021 revenues of USD 36.2 million versus USD 35.6 million in the second quarter of 2021 and an EBITDA loss of USD 3.7 million versus positive USD 7.9 million in the prior quarter. The Company reported EBITDA contributed by the semiconductor materials segment of USD 1.8 million for the third quarter compared to USD 11.5 million for the second quarter. Second quarter results included other income related to the forgiveness of a loan provided by the US government under the C.A.R.E.S. Act. Excluding this item, EBITDA decreased by USD 5.2 million. This decrease can primarily be attributed to higher electricity prices and lower production caused by the completion of planned maintenance activities and a delayed restart to mitigate high electricity prices. Silicon gas sales volumes for the third quarter were 728 MT compared to 819 MT during the prior quarter. Total polysilicon sales volumes for the quarter we